Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival

Study design awaiting verification · PLoS ONE · 2017

Original publication title

No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival

Li Luo; Irene Orlow; Peter A. Kanetsky; Nancy E. Thomas; Shenying Fang; Jeffrey E. Lee; Marianne Berwick; Ji-Hyun Lee; on behalf of the GEM Study Group

© 2017 Luo et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The prognostic improvement attributed to genetic markers over current prognostic system has not been well studied for melanoma. The goal of this study is to evaluate the added prognostic value of Vitamin D Pathway (VitD) SNPs to currently known clinical and demographic factors such as age, sex, Breslow thickness, mitosis and ulceration (CDF). We utilized two large independent well-characterized melanoma studies: the Genes, Environment, and Melanoma (GEM) and MD Anderson studies, and performed variable selection of VitD pathway SNPs and CDF using Random Survival Forest (RSF) method in addition to Cox proportional hazards models.

The Harrell’s C-index was used to compare the performance of model predictability. The population-based GEM study enrolled 3,578 incident cases of cutaneous melanoma (CM), and the hospital-based MD Anderson study consisted of 1,804 CM patients. Including both VitD SNPs and CDF yielded C-index of 0.85, which provided slight but not significant improvement by CDF alone (C-index = 0.83) in the GEM study. Similar results were observed in the independent MD Anderson study (C-index = 0.84 and 0.83, respectively). The Cox model identified no significant associations after adjusting for multiplicity.

Our results do not support clinically significant prognostic improvements attributable to VitD pathway SNPs over current prognostic system for melanoma survival.

Authors’ abstract

The prognostic improvement attributed to genetic markers over current prognostic system has not been well studied for melanoma. The goal of this study is to evaluate the added prognostic value of Vitamin D Pathway (VitD) SNPs to currently known clinical and demographic factors such as age, sex, Breslow thickness, mitosis and ulceration (CDF). We utilized two large independent well-characterized melanoma studies: the Genes, Environment, and Melanoma (GEM) and MD Anderson studies, and performed variable selection of VitD pathway SNPs and CDF using Random Survival Forest (RSF) method in addition to Cox proportional hazards models.

The Harrell’s C-index was used to compare the performance of model predictability. The population-based GEM study enrolled 3,578 incident cases of cutaneous melanoma (CM), and the hospital-based MD Anderson study consisted of 1,804 CM patients. Including both VitD SNPs and CDF yielded C-index of 0.85, which provided slight but not significant improvement by CDF alone (C-index = 0.83) in the GEM study. Similar results were observed in the independent MD Anderson study (C-index = 0.84 and 0.83, respectively). The Cox model identified no significant associations after adjusting for multiplicity.

Our results do not support clinically significant prognostic improvements attributable to VitD pathway SNPs over current prognostic system for melanoma survival.

Publication and source details

Original title: No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival

Li Luo; Irene Orlow; Peter A. Kanetsky; Nancy E. Thomas; Shenying Fang; Jeffrey E. Lee; Marianne Berwick; Ji-Hyun Lee; on behalf of the GEM Study Group

PLoS ONE · 2017

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: LL JHL.

  • Data curation: LL IO NET SF JEL MB.

  • Formal analysis: LL JHL.

  • Funding acquisition: NET MB JEL.

  • Methodology: LL JHL.

  • Supervision: MB JHL.

  • Visualization: LL IO PAK MB JHL.

  • Writing: original draft: LL MB JHL.

  • Writing: review & editing: LL IO PAK NET SF JEL MB JHL.

¶ Membership of the GEM Study Group is provided in the Acknowledgments.

* E-mail: LLuo@salud.unm.edu
© 2017 Luo et al2017Luo et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100000054National Cancer InstituteR01CA112243, R01CA112243-05S1, R33CA10704339Thomas Nancy E. http://dx.doi.org/10.13039/100000054National Cancer InstituteR01CA112524, R01CA112524-05S2,U01CA83180Berwick Marianne http://dx.doi.org/10.13039/100000054National Cancer InstituteR01CA098438http://dx.doi.org/10.13039/100000054National Cancer InstituteP30CA016086, P30CA008748, P30CA014089, P30CA118100http://dx.doi.org/10.13039/100000054National Cancer InstituteP50 CA093459Lee Jeffrey E. The University of Texas MD Anderson Cancer Center Various Donors Melanoma and Skin Cancers Priority Program FundLee Jeffrey E. the Miriam and Jim Mulva Research FundLee Jeffrey E. the McCarthy Skin Cancer Research Fund and the Marit Peterson Fund for Melanoma ResearchLee Jeffrey E. http://dx.doi.org/10.13039/100000066National Institute of Environmental Health SciencesP30ES010126Lee Jeffrey E. a University of Sydney Medical Foundation Program grant and a Michael Smith Foundation for Health Research Infrastructure AwardThis work was supported by National Cancer Institute (NCI) grants R01CA112243, R01CA112524, R01CA112243-05S1, R01CA112524-05S2, R01CA098438, U01CA83180, R33CA10704339, P30CA016086, P30CA008748, P30CA014089, and P30CA118100; the National Institutes of Health/National Cancer Institute Specialized Program of Research Excellence grant P50 CA093459; The University of Texas MD Anderson Cancer Center Various Donors Melanoma and Skin Cancers Priority Program Fund; the Miriam and Jim Mulva Research Fund; the McCarthy Skin Cancer Research Fund and the Marit Peterson Fund for Melanoma Research; the National Institute of Environmental Health Sciences (P30ES010126); a University of Sydney Medical Foundation Program grant (Bruce Armstrong); and a Michael Smith Foundation for Health Research Infrastructure Award (Richard Gallagher). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:56:40.986305+00:00

DOI: 10.1371/journal.pone.0174234 · PMC5360355